<DOC>
	<DOCNO>NCT01234129</DOCNO>
	<brief_summary>Assess impact outcome use zoledronic acid multiple myeloma .</brief_summary>
	<brief_title>Stem Cell Transplant Zoledronic Acid Improve Outcome Previously Untreated Patients With Multiple Myeloma</brief_title>
	<detailed_description>Assess use zoledronic acid improve outcome patient multiple myeloma whose treated cytoreductive therapy stem cell transplant .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Diagnosis multiple myeloma No previous treatment Symptomatic High risk ( ISS ) stage III ( DurieSalmon ) No severe comorbidities Pregnancy HIV + Refuse treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>stem cell transplant</keyword>
	<keyword>zoledronic acid</keyword>
</DOC>